Patents by Inventor John Wai

John Wai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240162224
    Abstract: An III-nitride power semiconductor based heterojunction device comprising a first heterojunction and a second heterojunction transistor, wherein the second heterojunction transistor has a substantially identical structure to the first heterojunction transistor, and wherein the second heterojunction transistor is scaled to a smaller area or gate perimeter than the first heterojunction transistor by a scale factor X, where X is larger than 1.
    Type: Application
    Filed: November 14, 2022
    Publication date: May 16, 2024
    Inventors: Florin Udrea, Loizos Efthymiou, Martin Arnold, John Findlay, Sheung Wai Fung, Tara Vishin, Paul Ryan
  • Publication number: 20240143013
    Abstract: A III-nitride power semiconductor based heterojunction device comprising a substrate, a first terminal, a second terminal, a control terminal configured to receive an input switching signal during an active mode of operation and to not receive the input switching signal during a stand-by mode of operation, and an active heterojunction transistor formed on the substrate.
    Type: Application
    Filed: October 31, 2022
    Publication date: May 2, 2024
    Inventors: Sheung Wai FUNG, Martin ARNOLD, Loizos EFTHYMIOU, Tara VISHIN, John William FINDLAY, Florin UDREA
  • Publication number: 20240141412
    Abstract: Described herein are nucleic acid detection compositions and systems comprising an internal nuclease chain reaction (NCR) for signal amplification and methods of using these NCR-containing compositions and systems.
    Type: Application
    Filed: May 18, 2021
    Publication date: May 2, 2024
    Inventors: David Savage, Patrick Hsu, Noam Prywes, Emeric J. Charles, Gavin J. Knott, John James Desmarais, Shineui Kim, Eli Dugan, Maria Lukarska, Sita S. Chandrasekaran, Nicholas C. Lammers, Tina Y. Liu, Amanda Mok, Liana Lareau, Brittney Wai-Ling Thornton
  • Publication number: 20240108844
    Abstract: A humidification system can include a heater base, a humidification chamber, and a breathing circuit. A cartridge can be removably coupled to the heater base. The cartridge can include various sensors, probes, sensor wire connectors, heater wire connectors, and/or other features. The cartridge can include features configured to mate with corresponding features on the humidification chamber and the heater base. The cartridge includes a memory, such as an EEPROM, or other suitable storage device. When the cartridge is installed on the heater base, the memory is electrically connected to a processor and/or memory of the heater base. Various models of cartridges can be produced for use with different humidification chambers, breathing circuits, and/or therapies. A connector can be configured to couple an inspiratory conduit to an outlet port of the humidification chamber. The connector can provide a pneumatic connection to the outlet port and an electrical connection to the cartridge.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 4, 2024
    Inventors: Hamish Adrian OSBORNE, Gavin Walsh Millar, Stephen David Evans, Bruce Gordon Holyoake, James William Stanton, David Leon McCauley, Gareth Thomas McDermott, Nicholas James Michael McKenna, Myfanwy Jane Antica Norton, Adrian John Elsworth, Michael John Andresen, Jonathan Andrew George Lambert, Sandeep Singh Gurm, Tessa Hazel Paris, Joseph Nathaniel Griffiths, Ping Si, Christopher Gareth Sims, Elmo Benson Stoks, Dexter Chi Lun Cheung, Peter Alan Seekup, Po-Yen Liu, Richard Edward Lang, Paul James Tonkin, Ian Lee Wai Kwan
  • Publication number: 20240094195
    Abstract: The present invention relates to a method for assessing respiratory viral infections, the method includes preparing one or more precision-cut human bronchial tissues; exposing a cilia-rich epithelium within the precision-cut human bronchial tissues to establish an ex vivo model of human bronchus for viral infections; assessing infectivity, tropism, and pathogenesis of one or more respiratory viruses in the ex vivo model; and providing a semi-quantitative and normalized approach to supplement data from the ex vivo model of human bronchus for pandemic risk assessment of the one or more respiratory viruses. The present invention involves micro-dissection of bronchial tissues to expose the cilia-rich epithelium for ex vivo virus infection, along with a semi-quantitative approach for analyzing virus tropism and replication competence.
    Type: Application
    Filed: September 14, 2023
    Publication date: March 21, 2024
    Inventors: Chi Wai Michael CHAN, Pui Yan HUI, John Malcolm NICHOLLS, Hiu Ha CHING, Hau Yin Kevin FUNG
  • Publication number: 20230390587
    Abstract: An x-ray irradiation system includes a first x-ray tube constructed and arranged to be able to irradiate an object with at least a portion of a first x-ray beam emitted from the first x-ray tube, and a second x-ray tube constructed and arranged to be able to irradiate the object with at least a portion of a second x-ray beam emitted from said second x-ray tube simultaneously with said first x-ray beam. The first and second x-ray tubes are arranged such that the first and second x-ray beams are incident on, and intersect within, the object at respective first and second oblique angles to define a target volume such that a dose rate is substantially uniform as prescribed within said target volume.
    Type: Application
    Filed: October 15, 2021
    Publication date: December 7, 2023
    Applicant: The Johns Hopkins University
    Inventors: John Wai-Chiu WONG, Mohammad REZAEE, Iulian IORDACHITA
  • Publication number: 20230045776
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Patent number: 11479683
    Abstract: In one aspect, inks for use with a three-dimensional printing system are described herein. In some embodiments, an ink described herein comprises up to about 90 wt. % monofunctional curable material, up to about 10 wt. % difunctional curable material, and up to about 10 wt. % liquid rubber, based on the total weight of the ink, wherein the liquid rubber comprises one or more curable moieties. In some cases, the liquid rubber comprises one or more ethylenically unsaturated moieties. For example, in some instances, the liquid rubber comprises a butadiene acrylonitrile copolymer.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: October 25, 2022
    Assignee: 3D SYSTEMS, INC.
    Inventors: John Wai Fong, Patricia Wang
  • Publication number: 20220127265
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 11292927
    Abstract: In one aspect, inks for use with a three-dimensional printing system are described herein. In some embodiments, an ink described herein comprises up to about 90 wt. % monofunctional curable material, up to about 10 wt. % difunctional curable material, and up to about 10 wt. % liquid rubber, based on the total weight of the ink, wherein the liquid rubber comprises one or more curable moieties. In some cases, the liquid rubber comprises one or more ethyleneically unsaturated moieties. For example, in some instances, the liquid rubber comprises a butadiene acrylonitrile copolymer.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: April 5, 2022
    Assignee: 3D SYSTEMS, INCORPORATED
    Inventors: John Wai Fong, Patricia Wang
  • Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Publication number: 20210380825
    Abstract: In one aspect, inks for use with a three-dimensional printing system are described herein. In some embodiments, an ink described herein comprises up to about 90 wt. % monofunctional curable material, up to about 10 wt. % difunctional curable material, and up to about 10 wt. % liquid rubber, based on the total weight of the ink, wherein the liquid rubber comprises one or more curable moieties. In some cases, the liquid rubber comprises one or more ethylenically unsaturated moieties. For example, in some instances, the liquid rubber comprises a butadiene acrylonitrile copolymer.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 9, 2021
    Inventors: John Wai Fong, Patricia Wang
  • Patent number: 11168070
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 9, 2021
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Publication number: 20210236473
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: February 25, 2021
    Publication date: August 5, 2021
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Patent number: 11034698
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, James Richard Kiefer, Jr., Jun Liang, Naomi S. Rajapaksa, Yongsheng Chen, Liqiang Fu, Kwong Wah Lai, Zhiguo Liu, John Wai, Fei Wang
  • Publication number: 20210113164
    Abstract: An integrated computed tomography (CT) treatment couch system may include a base platform configured to couple to a rotatable floor component associated with a medical accelerator, a pedestal component mounted to the base platform, a treatment couchtop disposed on the pedestal component, and a CT scanner device. The CT scanner device may include a support structure and a CT gantry. The support structure may be mounted to the base platform or to the pedestal component. The CT gantry may have a bore and may be oriented such that the bore is in line with the treatment couchtop. The CT gantry may be configured to generate on-line helical CT scans to guide radiotherapy provided by the medical accelerator.
    Type: Application
    Filed: December 28, 2020
    Publication date: April 22, 2021
    Applicant: The Johns Hopkins University
    Inventors: John Wai-Chiu WONG, Jeffrey H. SIEWERDSEN, Junghoon LEE
  • Patent number: 10966963
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 6, 2021
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Publication number: 20200399244
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 24, 2020
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 10729738
    Abstract: The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Jinhua Chen, John Wai
  • Patent number: 10696655
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 30, 2020
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang